Medindia

X

St. Paul and Atlanta Laboratories of WuXi PharmaTech (NYSE:WX) Receive ISO/IEC 17025:2005 Accreditation

Monday, January 12, 2009 General News J E 4
Advertisement
SHANGHAI, China, Jan. 12 WuXi PharmaTech (NYSE: WX),a leading pharmaceutical, biotechnology and medical device research anddevelopment outsourcing company with operations in China and the United States,announced today that its testing laboratories in St. Paul and Atlanta hadrecently received ISO/IEC 17025:2005 accreditation for technical competence inthe field of biological testing for a defined scope of operations, includingbiocompatibility testing and microbiology. The accreditation was receivedfrom the American Association for Laboratory Accreditation, which conducted areview and field audit of both sites using personnel with expertise specificto the kinds of testing these sites perform.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

ISO standards are set by the International Organization forStandardisation (ISO), a network of national standards institutes of 157countries. The International Electrotechnical Commission (IEC) createsstandards for applications in electricity, electronics, and related fields.These standards cover a wide range of industries and are based onauthoritative international practice. ISO/IEC 17025 standards for which theaccreditation was recently achieved in St. Paul and Atlanta specifically coverthe competence requirements of testing and calibration laboratories.

To obtain this accreditation, the laboratory must demonstrate competencein both management and technical requirements. Management requirements coverthe effective operation of a quality management system. Technicalrequirements relate to the competence of staff, the correctness of testingmethodologies, the adequacy of equipment, and the accuracy of results. Toobtain accreditation, the laboratory must submit to a thorough review of itsprocesses and procedures, including observation of actual testing beingundertaken. The lab must make use of the latest scientific and technicalknowledge, conduct internal audits, demonstrate continual improvement, andcommunicate effectively with customers. WuXi's ISO/IEC 17025:2005accreditation is for a renewable two-year period.

"Receiving ISO/IEC 17025 accreditation is further demonstration of thequality of our laboratory testing and the competence of our technicians," saidEdward Hu, Chief Operating Officer. "We initially sought conformity toISO/IEC 17025:2000 standards (issued in 2000) at the specific request of amedical device client. We proactively pursued accreditation to ISO/IEC17205:2005 standards (issued in 2005) to continue satisfying our valuedcustomers. The company's responsiveness not only satisfied a valued customer,but it also now equips WuXi PharmaTech with a credential it will use todemonstrate to new and existing clients that our testing procedures meet thehighest standards of excellence. Few of our competitors have ISO/IEC 17025accreditation."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medicaldevice R&D outsourcing company, with operations in China and the United States.As a research-driven and customer-focused company, WuXi PharmaTech providespharmaceutical, biotechnology and medical device companies a broad andintegrated portfolio of laboratory and manufacturing services throughout thedrug and medical device R&D process. WuXi PharmaTech's services are designedto assist its global partners in shortening the cycle and lowering the cost ofdrug and medical device R&D. The operating subsidiaries of WuXi PharmaTechare known as WuXi AppTec. For more information, please visit:http://www.wuxiapptec.com .For more information, please contact: Ronald Aldridge Director of Investor Relations WuXi PharmaTech (Cayman) Inc. Tel: +1-215-218-5515 Email: ir@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Singulex Closes $19 Million Financing Round
S
MAP Pharmaceuticals Provides Update on Progress of...